文献速递肝病

非靶向脂质组学揭示区分失代偿期肝硬化严重程度的脂质特征

Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2021-07-07

本研究在561例急性失代偿(AD)肝硬化患者(发现队列)和265例AD患者(验证队列)中行血清非靶向脂质组学,另分析78例AD患者(含白蛋白治疗试验)。发现cirrhosis相关脂质普遍抑制,AD与ACLF各有特异脂质指纹,肝功能障碍和感染为主要贡献因素,白蛋白治疗后溶血磷脂酰胆碱水平升高。

要点

  • 肝硬化急性失代偿患者循环脂质普遍抑制,非存活者更明显。
  • 鞘磷脂指纹可区分代偿与失代偿肝硬化,胆固醇酯和溶血磷脂酰胆碱指纹区分ACLF。
  • 脂质指纹动态可变,白蛋白治疗后溶血磷脂酰胆碱水平升高。

核心结论

  • 肝硬化失代偿和ACLF进展伴随特定脂质景观改变,脂质指纹可作为无创诊断生物标志物。

研究设计与样本

  • 发现队列561例AD患者(518例无ACLF,43例有ACLF),验证队列265例AD患者(128例无ACLF,137例有ACLF)行血清非靶向脂质组学,验证队列在28天随访内重复测量。
  • 另分析78例AD患者(来自白蛋白治疗试验,含43例代偿期肝硬化和29例健康个体)。

主要发现

  • 肝硬化相关循环脂质景观表现为普遍抑制,在AD期间和非存活患者中更明显。
  • 通过计算223种注释脂质的判别准确性和变量重要性投影评分,鉴定出AD特异的鞘磷脂指纹和ACLF特异的胆固醇酯及溶血磷脂酰胆碱指纹。
  • 肝功能障碍和感染是这些指纹的主要净贡献因素,指纹在恶化至ACLF或改善的AD患者间动态且可互换。
  • 白蛋白治疗后患者血溶血磷脂酰胆碱水平升高。

临床怎么用

  • 脂质指纹可能用于无创区分代偿与失代偿肝硬化,并识别有器官衰竭风险的失代偿患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute decompensation (AD) of cirrhosis is a heterogeneous clinical entity associated with moderate mortality. In some patients, this condition develops quickly into the more deadly acute-on-chronic liver failure (ACLF), in which other organs such as the kidneys or brain fail. The aim of this study was to characterize the blood lipidome in a large series of patients with cirrhosis and identify specific signatures associated with AD and ACLF development. METHODS: Serum untargeted lipidomics was performed in 561 patients with AD (518 without and 43 with ACLF) (discovery cohort) and in 265 patients with AD (128 without and 137 with ACLF) in whom serum samples were available to perform repeated measurements during the 28-day follow-up (validation cohort). Analyses were also performed in 78 patients with AD included in a therapeutic albumin trial (43 patients with compensated cirrhosis and 29 healthy individuals). RESULTS: The circulating lipid landscape associated with cirrhosis was characterized by a generalized suppression, which was more manifest during AD and in non-surviving patients. By computing discriminating accuracy and the variable importance projection score for each of the 223 annotated lipids, we identified a sphingomyelin fingerprint specific for AD of cirrhosis and a distinct cholesteryl ester and lysophosphatidylcholine fingerprint for ACLF. Liver dysfunction and infections were the principal net contributors to these fingerprints, which were dynamic and interchangeable between patients with AD whose condition worsened to ACLF and those who improved. Notably, blood lysophosphatidylcholine levels increased in these patients after albumin therapy. CONCLUSIONS: Our findings provide insights into the lipid landscape associated with decompensation of cirrhosis and ACLF progression and identify unique non-invasive diagnostic biomarkers of advanced cirrhosis. LAY SUMMARY: Analysis of lipids in blood from patients with advanced cirrhosis reveals a general suppression of their levels in the circulation of these patients. A specific group of lipids known as sphingomyelins are useful to distinguish between patients with compensated and decompensated cirrhosis. Another group of lipids designated cholesteryl esters further distinguishes patients with decompensated cirrhosis who are at risk of developing organ failures.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Clària J, Curto A, Moreau R, et al. Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis. J Hepatol. 2021. PMID: 34245803. doi:10.1016/j.jhep.2021.06.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。